Nausheen Ahmed
Overview
Explore the profile of Nausheen Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dileo R, Mewawalla P, Babu K, Yin Y, Strouse C, Chen E, et al.
Blood Cancer J
. 2025 Mar;
15(1):34.
PMID: 40064854
While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple...
2.
Kharfan-Dabaja M, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40025178
Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multicenter, observational study we aimed to assess the safety...
3.
Lutfi F, Ahmed N, Hoffmann M, Tun A, McGuirk J
Clin Adv Hematol Oncol
. 2025 Jan;
22(10):510-519.
PMID: 39820375
The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or refractory disease. Herein, we review...
4.
Bansal R, Wiedel A, Hastings R, Boutz F, Abdelhakim H, Ahmed N, et al.
J Clin Apher
. 2025 Jan;
40(1):e70004.
PMID: 39810305
Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of...
5.
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al.
Blood Adv
. 2025 Jan;
PMID: 39786391
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of...
6.
Sainatham C, Yadav D, Dilli Babu A, Tallapalli J, Kanagala S, Filippov E, et al.
Front Med (Lausanne)
. 2024 Dec;
11:1462307.
PMID: 39697210
Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent a transformative approach to cancer treatment, harnessing...
7.
Riedell P, Grady C, Nastoupil L, Luna de Abia A, Luna A, Ahmed N, et al.
Blood Adv
. 2024 Dec;
9(5):1232-1241.
PMID: 39657136
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma. We present a multicenter retrospective study evaluating safety, efficacy,...
8.
Merz M, Dima D, Hashmi H, Ahmed N, Stolzel F, Holderried T, et al.
Blood Cancer J
. 2024 Dec;
14(1):214.
PMID: 39632797
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies...
9.
Rashid A, Wesson W, Abdallah A, Snyder J, Venkatesh P, Mushtaq M, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(1):52-57.
PMID: 39516088
Background: Recent approvals of chimeric antigen receptor T-cells (CAR T) and bispecific antibody therapies offer new hope for relapsed refractory multiple myeloma (RRMM) patients, with superior efficacy over standard regimens...
10.
Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, et al.
Blood Adv
. 2024 Oct;
9(1):170-175.
PMID: 39437770
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can affect a...